TECH · Q3 2026 Earnings

Bearish

Bio-Techne

Reported May 6, 2026

30-second summary

Bio-Techne's Q3 FY2026 organic revenue declined 2% — a step worse than the "consistent with Q2 (flat)" framing management gave 90 days ago — and the Q4 guide of "approximately flat" organic now formally retires the H2 mid-single-digit underlying ramp that anchored the FY low-single-digit posture for three consecutive quarters. Q3 adj. op margin of 34.2% was down 70bps YoY (vs 34.9%), but management reaffirmed the FY +100bps walk anchored on Q4 expansion vs prior-year Q4 of 32.0%. The bigger tell is in the script: management now openly anchors to "an acceleration in fiscal 2027" — a six-month deferral of the inflection that was supposed to arrive by Q4 FY2026 — and concedes the Q3 miss was forecasting overconfidence after two stabilization quarters, not a late-quarter operational surprise. The apples-to-apples underlying step-down (mid-singles ex-headwinds to low-singles ex-headwinds) is real but more modest than the bridge labels suggest, since the cell therapy drag itself moderated from ~300bps in Q3 to ~150bps in Q4.

Headline numbers

EPS

Q3 FY2026

$0.53

Revenue

Q3 FY2026

$0.31B

-2.0% YoY

Gross margin

Q3 FY2026

66.9%

Operating margin

Q3 FY2026

24.2%

Key financials

Q3 FY2026

Metric	Q3 FY2026	YoY	Q2 FY2026	QoQ
Revenue	$0.31B	-2.0%	$0.30B	+5.2%
EPS	$0.53	—	$0.46	+15.2%
Gross margin	66.9%	—	64.6%	+230bps
Operating margin	24.2%	—	18.4%	+580bps

Guidance

Q3 results broadly met prior guidance; company reaffirms FY2026 operating margin expansion target and guides Q4 as approximately flat organic growth with low single-digit underlying growth excluding cell therapy headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Organic revenue growth	Q3 FY2026	consistent with Q2 (flat)	-2%	in-line (flat expected, -2% actual; within qualitative range)	Met
Organic revenue growth (excluding cell therapy and OEM headwinds)	Q3 FY2026	mid-single digits	implied mid-single digits (Large Pharma double-digit, Proteomic mid-single-digit, Spatial Biology mid-teens)	in-line	Met
Cell therapy customer headwind impact	Q3 FY2026	approximately 300 basis points year-over-year	-2% overall organic growth	in-line (headwind magnitude consistent with prior expectations)	Met

New guidance

Metric	Period	Guide	YoY
Organic revenue growth	Q4 FY2026	approximately flat	approximately 0% YoY
Underlying growth (excluding cell therapy headwinds)	Q4 FY2026	low single-digit	low single-digit YoY
Adjusted operating margin expansion	Q4 FY2026	approximately 100 basis points over prior year	—

Reaffirmed unchanged this quarter: Operating margin expansion (full year) (100 basis points)

Segment KPIs

Q3 FY2026

Segment	Q3 FY2026	YoY
Protein Sciences	$0.226B	-1.0%
Diagnostics and Spatial Biology	$0.086B	-4.0%
Large Pharma Growth	Double-digit, 6 consecutive quarters	—
Proteomic Analysis Instruments Growth	Mid-single-digit	—
Spatial Biology Growth	Mid-teens	—
GMP Proteins Growth (excl. fast-track)	~50%	—

Other KPIs

Q3 FY2026

Segment	Q3 FY2026
Organic Revenue Growth	-2%
Adjusted Operating Margin	34.2%
Protein Sciences Segment Operating Margin	44.2%
Diagnostics and Spatial Biology Segment Operating Margin	12.1%

Management tone

Narrative arc: Retreat from double-digit (Q4 FY25) → Headwinds will subside (Q1 FY26) → Underlying growth ex-headwinds (Q2 FY26) → Acceleration deferred to FY27 (Q3 FY26)

The recovery has now been pushed out four consecutive quarters, and management openly conceded the forecasting error this quarter. In Q4 FY2025, "low single digits until headwinds subside" implied a back-half recovery. In Q1, "encouraging signs of stabilization" framed Q2 as the inflection. In Q2, "customer sentiment improving as we progress through calendar 2026" pushed the inflection to Q3-Q4. This quarter management explicitly said "our base case is that we won't see a meaningful uptick in growth until the first half of our fiscal year 2027" — a six-month deferral. More damning, in the Puneet Suda exchange management characterized the Q3 miss as forecasting overconfidence after two quarters of stabilization, not a late-quarter operational surprise. The forecasting discipline issue is now an acknowledged problem, not just an analyst concern.

The funding-recovery thesis got reframed from imminent translation to a structural lag explanation. Last quarter management cited the H2 2025 funding rebound as evidence the inflection was approaching. This quarter the same data point — "biotech funding activity has since rebounded meaningfully, with estimate increases of more than 90% and 50% in our fiscal Q2 and Q3, respectively" — gets paired with a defensive 2-3 quarter lag framework that mathematically pushes inflection into H1 FY2027. The funding signal didn't change; the interpretation did. Worse, the Matt Leroux exchange revealed that early-stage biotech funding (which drives core reagent sales) actually declined — late-stage funding shifted from 75% to 82% of total biotech budgets, hollowing out the very customer cohort Bio-Techne serves on reagents.

"Biotech end market is the biggest swing factor" is a concession of limited control. Management's tone this quarter shifted from confidence in portfolio-led acceleration to acknowledgment that the core growth driver is outside their hands. "Given the timing lag between funding and spending by biotech customers, which typically is two to three quarters, we believe this end market is the biggest swing factor for growth to accelerate from here." This is a meaningful narrative move — Q4 FY25 framed Bio-Techne as the company that would outpace the market by 500bps; Q3 FY26 frames the company as a passenger waiting for a biotech spending cycle they cannot control.

Margin conviction remains the one place tone is firm. Adjusted op margin of 34.2% landed within the 33-35% Q3 comp range the watch list flagged, and the FY +100bps walk was reaffirmed with conviction (anchored on Q4 expansion vs Q4 FY2025's 32.0%). In a print this soft on the top line, the margin discipline is the only credible commitment management is still making.

Recurring themes management leaned on this quarter:

Biotech funding recovery with extended 2-3 quarter spending lagLarge pharma resilience (6 consecutive quarters double-digit growth)Cell therapy FDA fast-track designation creating near-term GMP headwindsSpatial biology platform momentum (COMET 65% growth, record backlog)AI as data-generation enabler for discovery and internal protein designGeographic diversification with China stabilization (4 consecutive quarters growth)

Risks management surfaced:

Emerging biotech spending deferred due to 2-3 quarter funding-to-spending lagOrder timing lumpiness in diagnostics portfolio from large customer concentrationUnfavorable product mix pressuring gross margin (70.4% vs 71.6% YoY)U.S. government shutdown impacting grant activity and NIH fund outlays in Q3Foreign exchange headwinds (cited as $0.02 favorable but structural concern)

Q&A highlights

Matt Leroux · William Blair

Emerging biotech declined mid-single digits in Q2 and high single digits in Q3. Asked about inter-quarter trends from January through April and visibility on improvements given funding recovery.

Management acknowledged biotech was a surprise. Explained that while funding improved significantly (90% growth in Q4 calendar 2025, strong growth continuing into calendar 2026), early-stage biotech funding (which drives core reagent sales) actually declined, offsetting late-stage improvements. Two quarters of negative mid-single digit performance shifted to negative high single digits. Management is assuming flattish performance without clear stabilization indicators.

Q4 2025 funding up 90% in biotechTwo consecutive quarters of negative mid-single digit biotech market performanceStep down to negative high single digits in current quarterEarly-stage biotech funding down despite late-stage funding substantially up

Puneet Suda · Learing Partners

Asked about mid-single-digit growth feasibility for fiscal 2027 given market challenges, and whether biotech surprise was late-quarter or forecasting-related. Also questioned core reagents softness and potential share loss versus competitors showing recovery.

Management confident in mid-single-digit growth for FY27 based on market normalization indicators. Explained Q3 surprise was not late-quarter but rather forecasting overconfidence after two stabilization quarters. Addressed reagents: excluding a large OEM customer order swap between Q2-Q3, proteins and antibodies grew low single digits; market position remains strong versus competitors. Highlighted proteomic analysis and spatial biology as leading indicators of market inflection.

Management expects at least mid-single-digit growth in FY27Excluding three company-specific customers, would have been low single-digit growth even in current tough environment100 basis point order swap between Q2-Q3 affected core reagents comparisonProteins and antibodies grew low single digits in Q3 (excluding OEM timing)

Patrick Donnelly · Citi

Asked about China market momentum and visibility going forward. Also asked about biotech customer conversations and expected inflection timing given strong funding environment over past six months.

China posting fourth consecutive quarter of positive growth with momentum in advanced therapeutics, CROs, and CDMOs. Management visited China, met with government and customers, expecting continued strengthening. On biotech, acknowledged funding has been strong for six months but explained 2-3 quarter historical lag between funding and revenue recognition; only two quarters of solid funding so far, so average 2-3 quarter lag suggests inflection likely in back half of calendar 2026 (H1 FY27).

Fourth consecutive quarter of positive growth in ChinaManagement visited China this quarter and met with government officialsStrong activity in advanced therapeutics segmentHistorical funding-to-revenue lag ranges 1-4 quarters, averaging 2-3 quarters

Justin Bowers · Deutsche Bank

Asked for Q4 outlook by end market, competitive dynamics uncovered in funding analysis, and which portfolio parts would recover soonest from biotech customers.

Q4 base case assumes same performance as Q3 across all end markets: pharma strong (double digits), academic improving slowly, biotech flat at Q3 levels with potential upside but not in base case. Regarding biotech funding shift: 75% to 82% shift toward late-stage clinical funding away from early-stage discovery (25% down to 18% of budgets). This explains core reagent softness, not competitive dynamics. Proteomic analysis and spatial biology are early recovery indicators.

Q4 base case: pharma double-digit growth, academic modest improvement, biotech flat year-over-yearLate-stage biotech funding increased from 75% to 82% of total biotech fundingEarly-stage discovery funding declined from 25% to 18% of biotech budgetsProteomic analysis and spatial biology identified as portfolio early indicators of biotech inflection

Kyle Boucher · TD Cowan

Asked for clarification on Q4 flat organic guidance despite fewer discrete headwinds (GMP 150bps, OEM timing behind), easiest comps, and what else could be deteriorating. Also asked about sustainability of GMP reagent (~50% growth) and Lunafor (~60% growth).

Q4 flat organic driven primarily by biotech weakness; other end markets stable/improving (pharma double-digit, academic stabilizing, China positive). No additional deterioration drivers. On GMP/cell therapy: strong growth supported by expanding pipeline (18 programs in Phase 2 vs 15 previously, 6 in Phase 3), customer expansion (3% increase), deepening spend by existing customers. Set bar at 20% minimum sustainable growth given clinical stage progression and global cell therapy trial increases.

Q4 guidance flat organic; GMP reagent headwind 150 bps (small contributor to guide)OEM reagent timing headwind clearedCell therapy: 85 clinical programs, 18 in Phase 2 (up from 15), 6 in Phase 3Cell therapy customer count up 3% despite churn

Answers to last quarter's watch list

Whether Q3 organic lands at flat (the new guide) or slips negative — Organic declined 2%, missing the "consistent with Q2 (flat)" guide by ~200bps. Ex-headwind underlying growth landed at mid-singles as guided (Large Pharma double-digit, Spatial Biology mid-teens, Proteomic mid-single-digit), validating the bridge math but confirming the FY low-single-digit posture is now arithmetically unworkable given Q1 -1%, Q2 0%, Q3 -2%, Q4 guided flat. Status: Resolved negatively

Protein Sciences op margin trajectory against the tough YoY comp — Segment op margin of 44.2% remained well above corporate but was down 140bps YoY (vs 45.6%) on unfavorable mix and volume deleverage. Mixed signal, not the clean positive the prior framing assumed. Status: Resolved neutrally

Spatial Biology standalone organic growth disclosure — Management provided a qualitative "mid-teens" growth print for Spatial Biology this quarter, with COMET cited at 65% growth and record backlog. The standalone disclosure finally arrived, and the number cleared the +5% threshold by a wide margin. Status: Resolved positively

Whether the FY +100bps margin walk holds against the tougher Q3 YoY comp — Q3 adj. op margin of 34.2% was down 70bps YoY but landed within the 33-35% range the watch flagged, and management reaffirmed the FY +100bps walk anchored on Q4 expansion vs Q4 FY2025's 32.0%. The margin commitment is intact. Status: Resolved positively

GMP business underlying growth normalization — GMP Proteins grew ~50% excluding fast-track customers in Q3, supporting the underlying normalization claim. The fast-track headwind is now sized at 150bps for Q4 (down from 300bps in Q3), with full rolloff entering FY2027. The clinical pipeline expanded to 85 programs total, 18 in Phase 2 (up from 15), and 6 in Phase 3 — supportive of the 20% minimum sustainable cell therapy growth claim. Status: Resolved positively

What to watch into next quarter

Whether Q4 organic delivers the "approximately flat" guide or slips negative for the third consecutive quarter — three consecutive quarterly guides have come in worse than telegraphed (Q1 -1% vs. flat, Q2 0% vs. low-singles, Q3 -2% vs. flat). A Q4 print below -1% reported organic would mark four consecutive guidance misses and force management to either issue a formal FY2027 numerical guide or lose remaining credibility on near-term forecasting.

Whether management introduces a numerical FY2027 organic growth or revenue guide alongside the Q4 print — management has now anchored to "acceleration in fiscal 2027" three times this quarter without sizing it. The Suda exchange referenced "at least mid-single-digit growth" for FY27; watch whether that becomes a formal guide or stays qualitative. Continued qualitative-only framing would extend a now-five-quarter streak without a numerical FY commitment.

Whether early-stage biotech funding share recovers from 18% of biotech budgets toward the historical 25% — the Bowers exchange identified the funding mix shift (75%→82% late-stage; 25%→18% early-stage) as the structural explanation for core reagent weakness. Watch industry funding data into Q4 and Q1 FY2027 for evidence the mix is normalizing; sustained 80%+ late-stage concentration would push the reagents recovery beyond H1 FY2027.

Whether Diagnostics & Spatial Biology reported revenue returns to YoY growth as the exosome comp rolls off — segment organic growth was +3% in Q3 with reported -4% mechanically driven by the 8% exosome divestiture headwind. The underlying momentum (Spatial Biology mid-teens, COMET +65%) is intact; watch whether reported growth turns positive in Q4 as the exosome comp begins to clear.

Whether adjusted op margin holds the +100bps FY walk — Q3's 34.2% was down 70bps YoY but management reaffirmed the FY walk is closing via Q4. Watch whether Q4 op margin expands ~100bps over the Q4 FY2025 print of 32.0% (i.e. lands near 33%), which would confirm the FY walk closes as guided despite revenue softness.

Sources

Bio-Techne Q3 FY2026 press release, filed 2026-05-06 (SEC EDGAR, tech-20260506xex99d1.htm)
Bio-Techne Q3 FY2026 earnings call Q&A — analyst exchanges with William Blair, Leerink Partners, Citi, Deutsche Bank, TD Cowen

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.